Schering-Plough
Schering-Plough Corporation was an American pharmaceutical company. It was originally the U.S. subsidiary of the German company Schering AG, which was founded in 1851 by Ernst Christian Friedrich Schering. As a result of nationalization, it became an independent company. In 1971, the Schering Corporation merged with Plough, Inc. (founded by Memphis-based entrepreneur Abe Plough in 1908) to form Schering-Plough. On November 4, 2009 Merck & Co. merged with Schering-Plough with the new company taking the name of Merck & Co.
| Company type | Subsidiary |
|---|---|
| Industry | Pharmaceuticals |
| Founded | 1971 (by merger with Plough, Inc.) |
| Defunct | November 2009 |
| Fate | Merged with Merck & Co. |
| Headquarters | Kenilworth, New Jersey |
Key people | Fred Hassan Final CEO & Chairman |
| Revenue | US$18.502 billion (2008) |
| US$1.903 billion (2008) | |
| Parent | Merck & Co. |
Schering-Plough manufactured several pharmaceutical drugs, the most well-known of which were the allergy drugs Claritin and Clarinex, an anti-cholesterol drug Vytorin, and a brain tumor drug Temodar. These are now available from Merck & Co.
Schering-Plough also owned and operated the major foot care brand name Dr. Scholl's and the skin care line Coppertone. These also became a part of the new company.
As of June 2005, Schering-Plough had 1.4% market share in the U.S., placing it seventeenth in the top twenty pharmaceutical corporations by sales compiled by IMS Health.
Schering-Plough was a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA), a membership which is also maintained by the new Merck & Co.